Objectives-Activated T lymphocytes are involved in the pathogenesis of scleroderma (systemic sclerosis, SSc); such cells rapidly divide in vivo and are thus theoretically subject to random mutation more frequently than resting cells. To study whether SSc is associated with rapidly expanding T cell clones the frequency was determined of in vivo mutated T cells (MF) at the hypoxanthine guanine phosphoribosyl transferase (hprt) gene in the peripheral blood from patients with SSc.
involved in the pathogenesis of scleroderma (systemic sclerosis, SSc); such cells rapidly divide in vivo and are thus theoretically subject to random mutation more frequently than resting cells. To study whether SSc is associated with rapidly expanding T cell clones the frequency was determined of in vivo mutated T cells (MF) at the hypoxanthine guanine phosphoribosyl transferase (hprt) gene in the peripheral blood from patients with SSc. Specific clinical or serological associations were also investigated. Methods-Peripheral blood lymphocytes from 16 healthy individuals and 20 patients with SSc were cultured using an hprt clonal assay; mutated and wild T cell clones were established to assess individual values of T cell MF. T cell clones were further expanded in vitro and their phenotype was determined by standard immunofluorescence technique. Enzymelinked inmmunosorbent assays were used for simultaneous measurements ofplasma levels of soluble Interleukin-2 receptors (s-IL-2R) and Intercellular adhesion molecule-i (s-ICAM-1). Results-Mean (SD) value of T cell MF in patients with SSc was 2-5-fold higher than the normal mean (SD) value [10.6 (6-6) [(13.6 (7.4 )) x 106 v (7*5 (4-3)) x 10-, p = 0031, suggesting that increased T cell MF in SSc may reflect an ongoing process of chronic in vivo T cell proliferation and/or prolonged survival.
Conclusion-Increased in vivo T cell mutation in patients with SSc suggests that excessive division and/or survival ofT cell clones contribute to the pathology in SSc; this approach can be used in further investigations to identify the stimulus that is triggering T cell activation in this disease.
(Ann Rheum Dis 1994; 53: 122-127) Scleroderma (systemic sclerosis, SSc) is a systemic autoimmune disorder of unknown origin.' 2 T cell infiltration in early sclerodermatous lesions,3 as well as the presence of activated T cells in the peripheral blood of patients with SSc,4-6 suggests that T cells may either directly (by reacting to self endothelial cells),7 or indirectly, (through the release of cytokines such as interleukin 2, interleukin 4 and transforming growth factor-1)'0-12 play a central role in the development of vascular damage and fibrosis in patients with SSc. The hypothesis that a T cell-mediated autoimmune process is primarily involved in SSc is also suggested by its HLA class-II association. This hypothesis, however, remains unproven. l 2 Cells undergoing rapid division in vivo are subject to a higher rate of spontaneous somatic mutation, presumably as a result of errors in replication, insufficient DNA repair, or fixation of the mutation. An in vivo mutation therefore occurs more frequently in activated T cells compared with resting T cells. suspended and counted using a haemocytometer. Cells were inoculated at 5, 2, 1 and 0-5 cells per well to determine cloning efficiency (CE), in 0-2 ml of non-selection growth medium, in 96-well round bottom microtitre plates (Coming Glass Works, Coming, NY). The limiting dilution protocol was always the same. For each cell concentration, at least 144 wells were plated. Nonselection growth medium contained 65% RPMI-1 640 supplemented as described above, 5% FCS, 20% HL-1i 10% human T-STIM-'t without PHA, (an enriched mixture containing IL-2 and other lymphokines, Collaborative Research Inc., Bedford, MA), and 0.1 ,ug/ml PHA. In parallel, 2 x 104 cell per well were inoculated in selection medium (434 wells at least for each experiment) to determine the mutant frequency (MF). Selection medium was the non-selection growth medium as described above supplemented with 10-5 M of 6-thioguanine (2-amino-6-mercapto-purine; Sigma). Only the cells that carry a mutation at the hprt gene are 6-thioguanine resistant. As a source of feeder cells the human lymphoblastoid cell line WIL-2 that carries a mutation at the hprt gene, designated TK6, was used. Mycoplasma-free TK6 cells (American Type Culture Collection, Rockville, MD) were irradiated with 8000 rads from a '37Cs source and added (15 x 103 cells per well) in all wells.
In every experiment 72 wells containing growth medium and irradiated TK6 cells only served as negative control. The microcultures were incubated at 37°C in a humidified 5% CO2 atmosphere for 11 days to allow colony growth.
EVALUATION OF CLONING EFFICIENCY AND MUTANT FREQUENCY OF T CELLS
The microcultures were scored for colony growth at the end of the incubation period using a phase contrast inverted microscope. Wells were classified as positive or negative for growth. All colonies that are grown under these conditions contain exclusively T cells. 13 '9 Assuming a Poisson distribution of clonable cells in limiting dilution studies23 the cloning efficiency (CE) values for the platings of 5, 2, 1 and 0 5 cells per well were calculated as follows: CE = -ln (fraction of negative wells in non-selection medium)/number of cells per well.
The mutant frequency of T cells (MF) was determined as the ratio of the cloning efficiencies in selection and non-selection medium, as follows: MF = -ln (fraction of negative wells in selection medium)/2 X 104/mean CE, where mean CE is the mean of the CE values for the platings of 5, 2, 1 and 0 5 cells per well.
The CE values for the 5, 2, 1, and 0 5 cell! well platings do not represent the true cloning efficiency of T cells because the initial haemocytometer count does not distinguish between T and B cells or monocytes. However, the ratio of the cloning efficiencies in selection and nonselection medium, that is, the MF represents the true frequency of hprt mutant T cells because it compares T cell mutants to total clonable T-cells. The in vivo T cell MF in the peripheral blood of 20 patients with SSc and 16 healthy control individuals was determined using the hprt clonal assay. We studied three normal individuals repeatedly (table 1). The relatively low variance of three determinations in each of the subjects studied enabled us to conclude that the used clonal assay has acceptable reproducibility. The mean (SD) MF of the control group (n= 16) was [4 4 (2 8)] X 10-6 (range from 0,6 X 10-6 to 10,9 X 10-6). The T cell MF in the group of patients with SSc ranged from 1_9 X 10-6 to 30-2 X 10-6 (table 2), while the mean was 10-6 (6 6) x 10-6 that is, 2 5 times higher than the mean value of the control group (p = 0 0007). Eleven of 20 patients had values higher than 10 X 10-6 which is two SD above the mean value of the control group. The CE was almost similar in patients and controls [0-42 (0 24) and 0 44 (0 25) respectively], thus the difference of T cell MF between patients and controls was not due to differences in CE of T cells. (table 5) . It should be noted that the conditions of the clonal assay that we used to develop the above clone did not enable us to distinguish between doubly marked cells and a mixed population of singly marked cells. Similar results were obtained from the staining of the wild T cell clones that were derived from patients with SSc. A double negative (CD3+ cx,BCD4-CD8-) T cell clone was detected among the wild clones. The distribution of the mutant and wild T cell clones that were derived from healthy controls among various phenotypes did not differ (chi-square test) from the distribution of the SSc patient-derived clones (table 5). All CD4+ clones were activated, helper/inducer, memory T cells (HLADR+, CD25+, CD29+, CD45RA-, CD4RO+).
Discussion
In view of the information supporting an in vivo activation of T cells in SSc patients and the fact that in vivo acquisition of any random mutation occurs preferentially in dividing cells, we assumed that the frequency of mutated T cells is increased in the peripheral blood of patients with SSc. As previously reported, this assay detects mutations that have resulted from independent mutational events.'4 The majority of the patients studied had increased T cell MF, as assessed by the hprt clonal assay. Normal MF values in our hands are almost identical to normal values reported by those who developed and optimised the hprt clonal assay.'5 16 Eleven patients of a representative 
